

UCLA

UCLA Previously Published Works

Title

Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis

Permalink

<https://escholarship.org/uc/item/9t7460j7>

Journal

Cancer Discovery, 12(2)

ISSN

2159-8274

Authors

Togami, Katsuhiko
Chung, Sun Sook
Madan, Vikas
et al.

Publication Date

2022-02-01

DOI


10.1158/2159-8290.cd-20-1513

Peer reviewed

Sex-Biased *ZRSR2* Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis



Katsuhiro Togami¹, Sun Sook Chung¹, Vikas Madan², Christopher A.G. Booth¹, Christopher M. Kenyon¹, Lucia Cabal-Hierro¹, Justin Taylor^{3,4}, Sunhee S. Kim¹, Gabriel K. Griffin^{5,6}, Mahmoud Ghandi⁶, Jia Li², Yvonne Y. Li¹, Fanny Angelot-Delettre⁷, Sabeha Biichle⁷, Michael Seiler⁸, Silvia Buonamici⁸, Scott B. Lovitch⁵, Abner Louissaint Jr⁹, Elizabeth A. Morgan⁵, Fabrice Jardin¹⁰, Pier Paolo Piccaluga^{11,12,13}, David M. Weinstock^{1,6}, Peter S. Hammerman¹, Henry Yang², Marina Konopleva¹⁴, Naveen Pemmaraju¹⁴, Francine Garnache-Ottou⁷, Omar Abdel-Wahab³, H. Phillip Koeffler^{2,15,16}, and Andrew A. Lane^{1,6,17}



ABSTRACT

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive leukemia of plasmacytoid dendritic cells (pDC). BPDCN occurs at least three times more frequently in men than in women, but the reasons for this sex bias are unknown. Here, studying genomics of primary BPDCN and modeling disease-associated mutations, we link acquired alterations in RNA splicing to abnormal pDC development and inflammatory response through Toll-like receptors. Loss-of-function mutations in *ZRSR2*, an X chromosome gene encoding a splicing factor, are enriched in BPDCN, and nearly all mutations occur in males. *ZRSR2* mutation impairs pDC activation and apoptosis after inflammatory stimuli, associated with intron retention and inability to upregulate the transcription factor IRF7. *In vivo*, BPDCN-associated mutations promote pDC expansion and signatures of decreased activation. These data support a model in which male-biased mutations in hematopoietic progenitors alter pDC function and confer protection from apoptosis, which may impair immunity and predispose to leukemic transformation.

SIGNIFICANCE: Sex bias in cancer is well recognized, but the underlying mechanisms are incompletely defined. We connect X chromosome mutations in *ZRSR2* to an extremely male-predominant leukemia. Aberrant RNA splicing induced by *ZRSR2* mutation impairs dendritic cell inflammatory signaling, interferon production, and apoptosis, revealing a sex- and lineage-related tumor suppressor pathway.

INTRODUCTION

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a hematologic malignancy in which patients can have leukemic involvement of the blood and bone marrow, as well as tumor formation in the skin (in ~90% of cases), lymphoid organs, and other tissues (1). Among the unique epidemiologic features of the disease is the extreme male predominance, with a male/female incidence ratio of at least 3:1 in adults (2, 3). There is no explanation to date for why males are predisposed to the disease or, alternatively, why females are relatively protected. Outcomes for patients with BPDCN are poor, with a median survival of 12 to 24 months from diagnosis (3, 4), demonstrating the unmet need for additional biological insight.

DNA sequencing of bone marrow or skin involved with BPDCN has identified mutations in genes often affected in other blood cancers, particularly myelodysplastic syndrome (MDS) and related myeloid malignancies. These include point

mutations or insertion–deletion (indel)/frameshift mutations in *ASXL1*, *TET2*, and *TP53* and copy number alterations affecting one or more cell-cycle regulators (5–9). However, BPDCN frequently arises in the context of a preexisting or concurrent myeloid malignancy, such as MDS or chronic myelomonocytic leukemia (CMML; refs. 10–12), but most of the prior genetic landscape studies of BPDCN analyzed unsorted bone marrow or skin biopsy specimens with heterogeneous composition. Those biopsy specimens likely included hematopoietic cells, possibly neoplastic, of other lineages and nonhematopoietic cells. Therefore, one goal of this project was to define the genetic alterations and transcriptional changes present in highly purified BPDCN cells separated from any background clonal hematopoietic disorder and to link these to patient sex. We found that loss-of-function mutations in the RNA splicing factor *ZRSR2*, encoded on chromosome X, are enriched in BPDCN and associated with a significant fraction of the male predominance of the disease.

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. ²Cancer Science Institute of Singapore, National University of Singapore, Singapore. ³Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. ⁴Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, Florida. ⁵Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ⁶Broad Institute of Harvard and MIT, Cambridge, Massachusetts. ⁷Université Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France. ⁸H3 Biomedicine, Cambridge, Massachusetts. ⁹Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts. ¹⁰Inserm U1245, Centre Henri Becquerel, Université de Rouen, IRIB, Rouen, France. ¹¹Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University Medical School, Bologna, Italy. ¹²Department of Biomolecular Strategies, Genetics, Avant-Garde Therapies and Neurosciences (SBGN), Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy. ¹³School of Health, Department of Pathology,

Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya. ¹⁴Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. ¹⁵Cedars-Sinai Medical Center, Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, California. ¹⁶Department of Hematology-Oncology, National University Cancer Institute of Singapore (NCIS), National University Hospital, Singapore. ¹⁷Ludwig Center at Harvard, Boston, Massachusetts.

Corresponding Author: Andrew A. Lane, Dana-Farber Cancer Institute, 450 Brookline Avenue, Mayer 413, Boston, MA 02215. Phone: 617-632-4589; E-mail: andrew_lane@dfci.harvard.edu

Cancer Discov 2022;12:522–41

doi: 10.1158/2159-8290.CD-20-1513

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

©2021 The Authors; Published by the American Association for Cancer Research

BPDCN is thought to develop from plasmacytoid dendritic cells (pDC) or their precursors, based primarily on similarities in gene expression and cellular function (13–15). However, mechanisms of how genetic alterations promote leukemic transformation in the dendritic cell lineage are unclear. Furthermore, studies have not linked the myeloid neoplasm-associated mutations described in BPDCN to consequences on pDC development, growth, or function. Thus, a second goal of this work was to connect genes mutated in BPDCN to dendritic cell transformation via interrogation of their effects specifically in pDCs, myeloid/dendritic progenitors, and BPDCN cells. We found that *ZRSR2* mutations impair pDC activation and apoptosis in the setting of inflammatory stimuli, at least in part via misregulation of the interferon regulatory factor IRF7, downstream of Toll-like receptor (TLR) signaling.

RESULTS

BPDCN Has Male-Biased *ZRSR2* Mutations and a UV-Associated Signature

We performed whole-exome sequencing (WES) on sorted BPDCN (CD45⁺ CD4⁺ CD56⁺ CD123⁺ BDCA4⁺ CD3⁻; $n = 11$ patients) from blood or bone marrow and on paired CD3⁺ cells to identify acquired mutations in the malignant cells. We also performed targeted sequencing using a 95-gene panel in an extended set of bone marrow from patients with BPDCN ($n = 27$; ref. 16). The most frequently mutated genes across all BPDCN were *TET2*, *ASXL1*, and genes involved in RNA splicing, including *ZRSR2*, *SRSF2*, *U2AF1*, and *SF3B1* (Fig. 1A; Supplementary Table S1). Additional mutations included genes recurrently altered in other myeloid malignancies, such as *TP53*, *NRAS*, *KRAS*, and *GNB1*. Of potential clinical relevance, we found an oncogenic *IDH2* mutation in 4 of 38 cases (~11%), which we previously reported was associated with sensitivity to the *IDH2* inhibitor enasidenib in a patient with BPDCN (3). *TET2* and *IDH2* mutations were mutually exclusive, as has been reported in acute myeloid leukemia (AML; ref. 17). In contrast, other common myeloid malignancy-associated mutations were absent or rare, such as in *DNMT3A*, *NPM1*, or *FLT3-ITD* (FMS-like tyrosine kinase 3, internal tandem duplication). One BPDCN harbored a single-nucleotide variant (SNV) that encodes an IRF8^{R404W} missense mutation. Although the functional consequence of this specific variant is unknown, IRF8 is important for pDC development and function (18, 19). WES also identified a small number of recurrently mutated genes in this set of BPDCN that have not been previously identified as mutated in other cancers or in prior BPDCN sequencing (Supplementary Table S2). Some of these variants are in homopolymer tracts that are at risk for sequencing errors or are in genes that are not expressed in BPDCN or pDCs, and thus their contribution to the BPDCN phenotype is not clear.

In the BPDCN studied by WES, the distribution of variant allele frequency (VAF) for all somatic mutations allowed us to define their clonal structure (Fig. 1B). Most cases harbored known hematologic malignancy-associated genes in a single dominant clone (clustered around VAF ~50% for presumed heterozygous mutations), which included all of the variants in the most frequently mutated genes:

TET2, *ASXL1*, and spliceosome components. Some mutations were detected at nearly 100% VAF, including in *ZRSR2* and *BCORL1*, which reside on the X chromosome and were mutated nearly exclusively in males in this cohort, and in the autosomal genes *ETV6*, *IDH2*, and *TP53*, which likely represent loss-of-heterozygosity events.

Given that many genes mutated in BPDCN were shared with other myeloid malignancies, we asked if the global mutation pattern might indicate unique BPDCN-specific features. We performed a mutation analysis on all somatic alterations and their surrounding nucleotide context using signatures previously defined in the Catalog of Somatic Mutations in Cancer (COSMIC; ref. 20). We found that BPDCN harbored an age-associated pattern (signature 1), which is detected in most cancers in COSMIC (Fig. 1C; Supplementary Fig. S1). However, we also detected a strong association with UV-induced mutation signatures in most BPDCN (signature score >0.25 in 6/11 or 55%; Fig. 1C). In contrast, there was no UV signature associated with AML (0/101 cases, $P < 0.0001$ by Fisher exact test), even though AML shares many recurrently mutated genes with BPDCN and may arise from a similar myeloid progenitor. For comparison, melanoma harbors a uniformly high UV signature in most tumors (Fig. 1C). The BPDCN cells we analyzed were harvested from bone marrow or blood and not directly from UV-exposed tissue (i.e., skin), suggesting that at least some leukemic BPDCN cells maintain a UV signature presumably acquired during a prior skin phase of malignant evolution.

Sequencing purified BPDCN cells rather than bulk marrow or skin samples also allowed us to determine DNA copy number variants (CNV) that were more confidently BPDCN-associated. Some of the chromosome and arm-level CNVs were similar to those described previously in BPDCN (Fig. 2A; refs. 7, 21). These included loss of 7p (which harbors *IKZF1*), 9p (*CDKN2A*, *CDKN2B*), 12p (*CDKN1B*, *ETV6*), 13q (*RB1*), and 17p (*TP53*; Supplementary Fig. S2). Copy number analysis also clarified the disease genetics for patients 2 and 10, who did not have any SNVs in known blood cancer-associated genes from WES (Fig. 1A). In those patients, we detected deletions in *IKZF1* and *RB1* (patient 2) and *TET2*, *RB1*, and *ZRSR2* (patient 10), which supports that analysis of CNVs in addition to point mutations/indels can detect additional relevant driver events. Integrated analysis of SNVs/indels and copy loss highlighted four putative BPDCN tumor suppressors targeted by both types of alteration: *ZRSR2*, *TET2*, *TP53*, and *SETD2* (Fig. 2B). PCR confirmed the WES finding that chromosome Xp22.2 copy loss in patient 10, a male, resulted in complete absence of *ZRSR2* DNA in tumor but not in germline cells (Fig. 2C).

ZRSR2 mutations in BPDCN are of particular interest for several reasons. First, although other splicing factors are mutated across many solid and blood cancers, *ZRSR2* is nearly exclusively associated with myeloid disorders, such as MDS, CMML, and AML. However, in contrast to MDS, in which *SRSF2*, *SF3B1*, and *U2AF1* mutations are more common, *ZRSR2* was the most frequently mutated spliceosome gene in this BPDCN cohort. To confirm this finding in a larger and more geographically diverse cohort, we examined BPDCN DNA from three separate groups (from France, Italy, and MD Anderson Cancer Center) and found *ZRSR2* mutations




Figure 1. Recurrently mutated genes and UV light-induced global mutation signature in BPDCN. **A**, Comutation plot of SNVs and indels in BPDCN samples among genes recurrently mutated in other hematologic malignancies. Each column represents an individual patient; genes are in rows and mutation types are annotated by color. Percentages of patients with a given gene altered are plotted to the left. Samples are annotated by gender and sequencing method (WES). **B**, VAF of all somatic mutations (including synonymous) with VAF ≥ 0.1 detected by WES in 11 BPDCN plotted as gray dots. VAFs of known hematologic malignancy-related genes from **A** are annotated in red (autosomes) or blue (X chromosome). **C**, Global somatic mutational signatures in BPDCN, AML, and melanoma plotted as fraction of samples (x-axis) having a specific signature with the mean signature score in those patients (y-axis). The color of the circle represents a specific signature, and the size of the circle represents the strength of association as a combined measure of the fraction of patients having a signature and the contribution score.





in 24 of 93 patients (26%; Fig. 2D). This is significantly higher than the incidence of *ZRSR2* mutations in MDS, in which the gene was mutated in only 13 of 288 patients in one large cohort (4.5%; $P < 0.0001$ by Fisher exact test; ref. 22).

Second, nearly all *ZRSR2* mutations in our cohort were in males (mutated in 23 of 72 males vs. 1 of 21 females, $P = 0.011$ by Fisher exact test; Fig. 2E). The mutational pattern is consistent with loss of function, with most variants predicting inactivating events (nonsense, frameshift, deletion), which implicates *ZRSR2* as a male-biased X chromosome tumor suppressor gene. In fact, strictly defined inactivating mutations in our cohort were exclusively in males (16 of 72 males vs. 0 of 21 females, $P = 0.019$; Fig. 2E). This is similar to MDS, in which loss-of-function mutations in *ZRSR2* are almost always restricted to males (22). *ZRSR2* belongs to the minor subset of X chromosome genes that escape X inactivation silencing and is biallelically expressed in female cells (23). The finding that *ZRSR2* is also preferentially mutated in BPDCN and MDS from males strongly suggests

that *ZRSR2* is an escape from X inactivation tumor suppressor (EXITS) gene (24). As we previously described for other EXITS genes across a range of cancers, females are relatively protected from BPDCN because they have two active *ZRSR2* alleles and therefore require two mutations to eliminate function, whereas males require only one. The degree of sex bias in BPDCN incidence linked to *ZRSR2* can be expressed as the number of excess *ZRSR2* mutations in males per excess case of BPDCN in males (24). Using that calculation, in this cohort, 43% of the excess male risk of BPDCN is associated with a *ZRSR2* mutation.

Unique Transcriptomic Features of Spliceosome-Mutated BPDCN

Next, we asked how BPDCN transcriptomes relate to their genetics. We performed RNA sequencing (RNA-seq) on the same sorted BPDCN samples that we had profiled by WES. Peripheral blood pDCs (CD45⁺ CD123⁺ BDCA2⁺ CD3⁻) from healthy donors were analyzed in parallel for comparison



(Supplementary Table S3). Differentially expressed genes between BPDCN and pDCs were similar to those we previously defined that distinguished BPDCN from normal dendritic cells using single-cell RNA-seq (Fig. 3A; ref. 14). We also observed differences in individual oncogenes and tumor suppressors (*BCL2*, *MYB*, *IRF4*, and *MAP3K1*) known to be dysregulated in BPDCN (Fig. 3B). Furthermore, gene set enrichment analysis (GSEA) identified oncogene-associated signatures in BPDCN, including in both splicing factor mutated or wild-type compared with normal pDCs, such as overexpression of MYC and E2F targets, and of PI3K/AKT/MTORC1 signaling pathway genes (Fig. 3C). In addition to these expected gene expression changes, we also found that BPDCNs had upregulation of RNA splicing machinery and associated genes compared with normal pDCs (Fig. 3D). Furthermore, within BPDCN, splicing factor mutant cases showed upregulation of RNA splicing genes and were enriched for markers of active nonsense-mediated decay (NMD) RNA catabolism compared with BPDCN without *ZRSR2*, *SRSF2*, *SF3B1*, or *U2AF1* mutations (Fig. 3D), consistent with what has been observed in other spliceosome-mutant cancers (25, 26). This was of particular interest given that *ZRSR2* loss promotes intron retention (IR; ref. 27), which is known to trigger NMD activation and cause altered myelopoiesis (28).

Next, we analyzed RNA splicing in splicing factor-mutated BPDCN compared with normal pDCs and with BPDCN without any splicing factor mutation. BPDCN with splicing factor mutations showed several types of abnormal splicing, including IR, cryptic 3' splice site usage, and exon skipping (Supplementary Table S4). *ZRSR2*, *SRSF2*, *SF3B1*, and *U2AF1* are all involved in U2 intron splicing (99.7% of introns in the human genome). In contrast, *ZRSR2* is uniquely necessary for proper splicing of U12 introns (0.3% of human introns), an evolutionarily conserved genomic feature with distinct branch and splice site sequences (29, 30). In MDS, *ZRSR2* mutations promote aberrant IR with a bias toward retention of U12-type introns (31). Similarly, we found that BPDCNs with *ZRSR2* mutation or loss had increased IR compared with those without spliceosome mutations (Fig. 4A). Both U2- and U12-type introns were affected, but IR was markedly weighted toward U12-type introns in BPDCN with *ZRSR2* mutation (Fig. 4B). Consistent with possible activation of NMD, genes with an IR event in *ZRSR2*-mutant BPDCN had decreased expression compared with splicing factor wild-type BPDCN, albeit modestly across all IR events, versus genes without IR events (Supplementary Fig. S3A). We also detected some of the stereotypical missplicing patterns associated with specific splicing factor mutations in other cancers (31). These included preferential exon inclusion or exclusion related to CCNG/GGNG exonic splicing enhancer motifs in BPDCN with *SRSF2* mutation (32) and alternative 3' splice site usage with

SF3B1 mutation (Supplementary Fig. S3B and S3C; ref. 33). To confirm *ZRSR2*-associated splicing changes in a separate set of BPDCN, we analyzed patient-derived xenografts (PDX; ref. 34). We performed RNA-seq on six BPDCN PDXs, two with *ZRSR2* mutations and four without. Similar to what we observed in patient cells, PDXs with *ZRSR2* mutations had increased IR events that were biased toward aberrant retention of U12-type introns (Fig. 4B and C).

Next, we asked if the splicing abnormalities observed were directly related to loss of *ZRSR2*. The predominant nonsense and frameshift *ZRSR2* mutations we detected in BPDCN (Fig. 2D and E) are predicted to result in absence of a mature protein, which is what we observed by Western blotting in mutated compared with nonmutated BPDCN (Fig. 4D). Therefore, we used engineered knockdown or knockout cell line models to study *ZRSR2* mutations in BPDCN cells. First, we generated CAL1 BPDCN cell lines harboring doxycycline-inducible short hairpin RNAs (shRNA) targeting *ZRSR2* to model protein loss and facilitate time-dependent analysis of *ZRSR2* depletion effects on splicing (Fig. 4E). Seven days after induction of knockdown, IR was the most prominent acquired aberrant splicing event in sh*ZRSR2* compared with shControl cells (Fig. 4F). Both U2- and U12-type IR events were increased in *ZRSR2* knockdown cells (Fig. 4G), and IR events detected by RNA-seq could be confirmed by RT-PCR (Fig. 4H). Knockdown of the NMD factor UPF1 in *ZRSR2*-deficient cells led to increased *DERL3* RNA, one of the U12 genes consistently retained across BPDCN and cell lines with *ZRSR2* alterations, suggesting misspliced *DERL3* is subject to NMD (Supplementary Fig. S3D). Together, these experiments showed that U2- and U12-type IR is a consequence of *ZRSR2* depletion on RNA splicing in human BPDCN cells.

ZRSR2 Mutation Impairs pDC Activation and Apoptosis Induced by Inflammatory Stimuli

Genes that were misspliced in primary BPDCN with *ZRSR2*, *SRSF2*, or *SF3B1* mutations included several that are important in dendritic cell development and/or function, including *CSF2RB*, *IRF4*, *IRF7*, *IRF8*, and *LILRB4* (Supplementary Table S4). Therefore, to connect missplicing with cellular phenotype, we asked how *ZRSR2* mutations affect pDC function. *ZRSR2* knockdown was inversely correlated with expression of genes normally upregulated in TLR7 agonist (R848; resiquimod)-treated dendritic cells (Fig. 5A). This was of particular interest because studies have reported that primary BPDCN cells are less responsive to TLR/infectious stimulation than normal pDCs or have signatures of decreased activation, but the mechanisms are unknown (13, 35). To test if complete loss of *ZRSR2*, as we saw in patient samples, was sufficient to impair pDC activation, we stimulated CAL1 cells harboring CRISPR/Cas9 knockout of *ZRSR2* with TLR

Figure 2. *ZRSR2* mutations and their association with BPDCN sex bias. **A**, Somatic DNA copy number changes in 11 BPDCN identified by WES shown from blue (copy loss) to red (gain). **B**, Venn diagram showing the four genes with overlap of copy number variations (among 347 protein coding genes observed in at least two patients with VAF ≥ 0.2) and SNVs (among 54 targeted panel genes or protein coding gene mutations observed in at least two patients by WES). **C**, Sequencing read traces in the *ZRSR2* locus from WES and PCR of exon 10 DNA in tumor/germline pairs from representative BPDCN in males with intact or somatic copy number loss of *ZRSR2*. **D**, Schematic of the *ZRSR2* protein with amino acid locations and specific mutations ($n = 24$) detected in BPDCN ($n = 93$). **E**, *ZRSR2* mutations are male-biased. Twenty-three of 72 male BPDCN had *ZRSR2* mutations vs. 1 of 21 female BPDCN ($P = 0.011$ by Fisher exact test). When restricted to obvious loss-of-function (LOF) mutations (nonsense, frameshift, deletion; marked in red), 16 of 72 male BPDCN had *ZRSR2* LOF mutations vs. 0 of 21 female BPDCN ($P = 0.019$).




Figure 3. BPDCN transcriptomes have alterations in oncogene, dendritic cell development, and RNA processing genes. **A**, GSEA showing association of a previously defined gene signature from single-cell RNA-seq that differentiated BPDCN from normal human dendritic cell subtypes (14) in BPDCN ($n = 11$) compared with normal pDCs ($n = 4$) from the current cohort. Heat maps of the same genes plotted as low (blue) to high (red) relative expression. **B**, RNA expression of the indicated genes in BPDCN ($n = 11$) compared with normal pDCs ($n = 4$), with groups compared by *t* test. FPKM, fragments per kilobase of transcript per million mapped reads. **C**, GSEA comparing BPDCN with normal pDCs showing enrichment of the indicated hallmarks of cancer gene sets (MSigDB collection “H”) in BPDCN. **D**, GSEA as in **A** for the indicated RNA splicing and nonsense-mediated decay gene sets with heat maps of the top 20 leading-edge genes plotted as low (blue) to red (high) relative expression. In the indicated plots, BPDCN are separated by whether (Splicing Mut) or not (Splicing WT) they harbor a mutation in a splicing factor (*SF3B1*, *SRSF2*, *U2AF1*, or *ZRSR2*). ES, enrichment score; FDR, false discovery rate; NES, normalized enrichment score; WT, wild-type.





Figure 4. ZRSR2 mutations promote specific missplicing events. **A**, Intron retention events in BPDCN with a ZRSR2 mutation ($n = 2$, red) compared pairwise with normal pDCs ($n = 2$, noted as samples A and B) and to those events in BPDCN with no known splicing factor mutation ($n = 4$, gray). **B**, Density plots of frequencies of U2-type (blue) and U12-type (red) introns among aberrantly retained introns (Fisher exact test $P \leq 0.05$) in pairwise analyses of ZRSR2-mutant versus wild-type (WT) BPDCN and PDXs. $N = 2$ ZRSR2 mutant and $n = 4$ splicing factor wild-type in each. Dotted lines represent Δ MSI -0.2 and $+0.2$. **C**, RNA-seq reads of an aberrantly retained U12 intron (intron 4) in human DERL3 from BPDCN PDXs with or without ZRSR2 mutation (equivalent scale for all samples). **D**, Western blot for ZRSR2 and β -actin in CAL1 cells (parental or ZRSR2 knockout) and in BPDCN PDXs with wild-type or mutant ZRSR2. **E**, Western blot from CAL1 cells at baseline (day 0) and at 2 and 7 days after doxycycline induction of nontargeting control or ZRSR2-targeted shRNAs. **F**, Missplicing events after knockdown of ZRSR2 from cells shown in **E**, calculated by pairwise comparison between ZRSR2 knockdown and controls ($n = 3$ biological replicates each) on days 0, 2, and 7 of doxycycline induction. The number (and percentage) of events on each day is depicted in a single bar colored by different types of missplicing events: intron retention (red), 3' cryptic splice site (green), and exon skip (blue). **G**, Density plots of frequencies of U2-type (blue) and U12-type (red) introns in pairwise analysis of CAL1 with ZRSR2 knockdown versus control on day 7 after the doxycycline induction (Fisher exact test $P \leq 0.05$), plotted as in **B**. **H**, Left, RNA-seq reads and RT-PCR from CAL1 cells after the induction of control or ZRSR2-targeted shRNA showing retention of DERL3 intron 4. Right, number of DERL3 intron 4 RNA-seq reads plotted for control and ZRSR2 knockdown cells at days 0, 2, and 7 after doxycycline shRNA induction ($n = 3$ biological replicates each, groups compared by t test).



agonists (Fig. 5B). Upregulation of the activation marker CD80 after stimulation with lipopolysaccharide (LPS; TLR4 agonist) or R848 (TLR7) was markedly reduced in cells with knockout of *ZRSR2* (Fig. 5C). Next, we assessed the same phenotype in primary human BPDCN and pDCs. BPDCN, across genotypes, had decreased induction of CD80 compared with pDCs after R848 stimulation (Fig. 5D). Knockdown of *ZRSR2* in otherwise normal primary pDCs also impaired the R848 response (Fig. 5E). These data suggest that loss of *ZRSR2* is one, but not necessarily the only, mechanism by which BPDCN cells are rendered hyporesponsive to TLR activation.

TLR stimulation of normal pDCs induces secretion of numerous inflammatory cytokines, including type 1 interferons (IFN α and IFN β). In contrast, CAL1 cells with *ZRSR2* knockout had defective secretion of several cytokines (e.g., IFN α , IFN β , IL6, TNF α) after LPS or R848 stimulation compared with controls (Fig. 5F). We also found similar defective cytokine production in primary BPDCN cells compared with normal pDCs upon stimulation with R848 (Fig. 5F). Of note, *ZRSR2* loss did not simply cause a complete block in TLR signaling or protein secretion because other cytokines were produced equivalently in *ZRSR2*-mutant cells and BPDCN cultures after stimulation (e.g., TRAILR1). Together, these data suggest that *ZRSR2* mutations in BPDCN cells cause defective activation and impaired secretion of specific cytokines, including type 1 interferons, in the setting of TLR stimulation.

After activation, normal pDCs undergo apoptotic cell death as part of a negative feedback process that limits the inflammatory response (36). We hypothesized that BPDCN-associated alterations might protect pDCs from apoptosis in the setting of TLR stimulation, and this could be a mechanistic link between spliceosome mutations and malignant transformation. Consistent with this model, we observed that gene expression changes in R848-stimulated primary BPDCNs compared with normal pDCs were enriched for decreased type 1 interferon and decreased apoptosis signatures (Fig. 5G and H; Supplementary Fig. S4A).


Next, we asked if loss of *ZRSR2* conferred protection from apoptosis in the setting of inflammation. We stimulated CAL1 cells with LPS or R848 and found that both initiated apoptosis as measured by activation of caspases 3 and 7 (Fig. 6A). Knockout of *ZRSR2* conferred relative protection from LPS- or R848-induced apoptosis (Fig. 6B). The growth

rate of CAL1 cells at steady state was not changed by *ZRSR2* mutation. In contrast, although growth of wild-type cells was inhibited by LPS, *ZRSR2* knockout cells were protected from LPS-induced growth arrest (Fig. 6C).

We confirmed the specificity of CRISPR knockout and that loss of *ZRSR2* was necessary for protection from apoptosis by demonstrating that reexpression of wild-type *ZRSR2* in mutant cells partially rescued the ability of LPS to induce apoptosis and impair growth (Fig. 6C and D). Finally, we confirmed that *ZRSR2*-mutant CAL1 cells had not simply lost the ability to undergo cell death. A downstream consequence of pDC stimulation is production of TRAIL, a TNF-family proapoptotic cytokine, which promotes autocrine and paracrine apoptosis (37, 38). Treatment with exogenous TRAIL promoted apoptosis equivalently in control and *ZRSR2*-mutant CAL1 cells, as well as in normal pDCs and BPDCN, demonstrating that the cell death response downstream of TRAIL was intact (Fig. 6D; Supplementary Fig. S4B). Furthermore, although *ZRSR2*-mutant CAL1 cells had decreased surface expression of the TRAIL receptor DR5 after exogenous TRAIL treatment, a known consequence of receptor internalization after ligand binding, they did not after LPS or R848 treatment, consistent with a lack of autocrine TRAIL production and stimulation (Supplementary Fig. S4C).

Collectively, these data suggested that *ZRSR2* mutation perturbs specific pathways downstream of TLRs that result in impaired activation-induced cell death. Although it is likely that multiple effects of splicing mutations contribute to BPDCN, we asked if any common targets across BPDCN might be involved in the hypoactivation phenotype. When we analyzed aberrant splicing across BPDCN harboring any splicing factor mutation, *IRF7* was among the overlapping candidates. The *IRF7* gene encodes a transcription factor, interferon regulatory factor 7, that is activated by TLR signaling and is important for induction of downstream genes, including type 1 interferons and TRAIL (39, 40). Interestingly, the *IRF7* mRNA transcript is not classified as having U12-type introns, but it does contain a similarly behaving so-called weak intron (intron 4) that is known to be subject to intron retention and NMD in normal dendritic cells during activation (41). Rate-limiting splicing is also a feature of U12-type introns and more generally of a group of genes (with either U2 or U12 introns) that participate in “programmed delayed splicing” associated with inflammatory response regulation

Figure 5. pDC activation by TLR stimulation is impaired by loss of *ZRSR2* and in BPDCN. **A**, GSEA of RNA-seq showing decreased enrichment of TLR7 (R848) stimulated genes in *ZRSR2* knockdown cells (sh*ZRSR2* versus shControl CAL1 cells, each after 7 days of doxycycline shRNA induction; $n = 3$ per condition). Heat map shows expression levels of the leading-edge genes in GSEA from blue (low) to red (high). **B**, Western blot for *ZRSR2* and β -actin in control or *ZRSR2* knockout CAL1 cells. NTG1 and NTG2 are independent nontargeting sgRNAs, and Sg1, Sg2, and Sg3 are independent *ZRSR2*-targeted sgRNAs, each assessed in biological triplicate samples. **C**, Mean fluorescence intensity (MFI) of cell surface CD80 on control or *ZRSR2* knockout CAL1 cells is shown after stimulation with either LPS or R848 ($n = 3$ biological replicates of each sgRNA, groups compared by t test). **D**, CD80 upregulation (Δ MFI; MFI stimulated-unstimulated) 24 hours after R848 stimulation in three sets of independent normal donor-purified pDCs and in 11 primary BPDCN PDXs, with groups compared by t test. **E**, Top, Western blot for *ZRSR2* and β -actin in parental CAL1 cells and in CAL1 cells with CRISPR knockout (*ZRSR2* KO) or transient knockdown (si*ZRSR2*) of *ZRSR2*. Bottom, CD80 upregulation after R848 treatment in primary pDCs from three independent healthy donors (pDC_1–3) each with seven to nine biological replicates each transfected with control or *ZRSR2* siRNAs, with groups compared by t test. **F**, Heat maps showing protein quantitation of the indicated cytokines in supernatants of control or *ZRSR2* knockout CAL1 cells ($n = 3$ independent biological replicates of each sgRNA, nontargeting or *ZRSR2* targeting) and normal pDCs or BPDCN PDXs (each column is from an independent individual donor or PDX) after stimulation with LPS or R848. BPDCN genotypes, left to right: splicing factor wild-type, splicing factor wild-type, *ZRSR2* mutant. **G**, GSEA of RNA-seq from R848-stimulated normal human pDCs or primary BPDCN PDXs that were *ZRSR2* mutated (*ZRSR2* Mut), any splicing factor mutated (SF Mut), or without known splicing factor mutation (SF WT). **H**, Bubble plot of enrichment scores from gene set variation analysis (GSVA) for the indicated type 1 interferon and apoptosis signatures from RNA-seq in normal pDCs (yellow) and BPDCN PDXs (blue, splicing factor mutated; purple, splicing factor wild-type) after treatment with R848.



at the level of RNA processing (42, 43). *IRF7* intron 4 was aberrantly retained in *ZRSR2*-mutant BPDCN (2 of 2), and the same intron–exon region was also misspliced in *SRSF2*-mutated (4 of 4) and *SF3B1*-mutated (1 of 1) cases but not in splicing factor wild-type BPDCN or in normal pDCs (Supplementary Table S4).

Therefore, we hypothesized that TLR stimulation of BPDCN with a *ZRSR2* mutation would result in impairment of IRF7 induction and downstream gene activation, including proapoptotic pathways. Indeed, whereas the baseline IRF7 protein levels were minimally affected by *ZRSR2* mutation, mutant CAL1 cells had impaired ability to increase IRF7 protein after LPS stimulation (Fig. 6E). Spliced *IRF7* RNA increased, as expected, after stimulation in both control and mutant cells, whereas *IRF7* intron 4 expression was selectively increased in mutant cells (Supplementary Fig. S5A and S5B), which supports that the impairment of IRF7 protein induction by LPS is associated with IR. Induction of TRAIL was also impaired in *ZRSR2*-mutant cells, as expected for an IRF7 target gene (Fig. 6E). IRF7 and TRAIL induction by LPS were partially rescued in *ZRSR2*-mutant cells by overexpression of wild-type *ZRSR2* (Fig. 6E). Furthermore, expression of an intronless, constitutively active IRF7 (44) impaired growth of both wild-type and *ZRSR2*-mutant cells (Supplementary Fig. S5C). This suggested that loss of *ZRSR2* affected the induction of IRF7 protein after LPS stimulation, but function downstream of activated IRF7 remained intact.

We also generated *ZRSR2*-deficient CAL1 cells with an intronless wild-type or transcriptionally inactive IRF7 cassette knocked into the *IRF7* endogenous locus. Wild-type intronless IRF7, which would not require *ZRSR2* for splicing, restored LPS-induced growth arrest in *ZRSR2*-mutant cells, whereas inactive *IRF7* did not (Supplementary Fig. S5D). Finally, we asked if impaired IRF7 upregulation after TLR stimulation was seen in primary BPDCN cells. In contrast to normal pDCs, *ZRSR2*-, *SRSF2*-, and *SF3B1*-mutant BPDCN failed to upregulate IRF7 protein after stimulation (Fig. 6F). Two splicing factor wild-type BPDCN had normal IRF7 upregulation after TLR stimulation, which is consistent with the RNA splicing analysis in which *IRF7* was affected in all splicing factor mutant compared with nonmutant BPDCN. Together, these data support a model in which *ZRSR2* mutations provide a growth advantage in the setting of TLR activation, at least in part by impairing IRF7 induction and activation-induced apoptosis (Fig. 6G). Given that impaired activation is observed in malignant cells across several genotypes,

other disease-associated alterations may also contribute to this general feature of BPDCN.


BPDCN-Associated *Zrsr2* and *Tet2* Mutations Promote Aberrant pDC Phenotypes *In Vivo*

To evaluate the contribution of BPDCN-associated mutations to pDC development and function *in vivo*, we generated bone marrow chimeras with hematopoietic cells harboring mutations in *Zrsr2*, *Tet2*, or both. *Tet2* was chosen because it is the most frequently mutated gene in BPDCN and is the most commonly co-occurring mutated gene in BPDCN with mutated *ZRSR2* (Fig. 1A). We harvested c-kit⁺ bone marrow cells from Rosa-Cas9 knock-in animals, transduced with lentiviruses encoding single-guide RNAs (sgRNA) targeting *Zrsr2*, *Tet2*, or control nontargeting guides in pairwise fashion, each coexpressing GFP or tagRFP. Eight weeks after transplantation of transduced marrow into lethally irradiated wild-type recipients, we observed approximately equivalent single- and double-positive GFP/tagRFP cells in the bone marrow across genotypes (Fig. 7A). We confirmed CRISPR indel events at sgRNA target sites qualitatively and quantitatively using a T7 endonuclease assay and by bar-coded pooled sequencing (Supplementary Fig. S6A and S6B).

We compared the GFP/tagRFP double-positive populations in each of the four recipient groups (sgControl/sgControl, sg*Zrsr2*/sgControl, sgControl/sg*Tet2*, and sg*Zrsr2*/sg*Tet2*). We focused on dendritic cells and their precursors, but we also analyzed other hematopoietic stem and progenitor cell (HSPC) populations. *Zrsr2* and *Tet2* targeting was associated with relative expansion of lineage-negative, Sca1⁺, c-kit⁺ (LSK) HSPCs; common myeloid progenitors; and megakaryocyte–erythroid progenitors in the bone marrow (Supplementary Figs. S7, S8A and S8B). In dendritic cell development, common dendritic progenitors (CDP) differentiate into conventional dendritic cells (cDC) and pDCs. In recipients of transduced and transplanted bone marrow, CDP and cDC percentage and absolute number were not different in *Zrsr2*, *Tet2*, or *Zrsr2*/*Tet2* double mutants compared with controls. In contrast, pDCs were modestly expanded, particularly in *Tet2* and *Zrsr2*/*Tet2* double-mutant bone marrow (Fig. 7B; Supplementary Fig. S8A and S8B).

We assessed the transcriptome of mutant cells by sorting pDCs from bone marrow and performing RNA-seq. GSEA in mutant pDCs was negatively correlated with gene sets associated with DC activation and positively correlated with signatures of IFN α receptor knockout dendritic cells exposed to viral infection (Fig. 7C). This suggests that mutant mouse

Figure 6. *ZRSR2* mutation impairs pDC apoptosis following TLR stimulation, associated with blunted IRF7 and TRAIL induction. **A**, Caspase 3/7 activity in parental CAL1 cells after treatment with LPS or R848 compared with vehicle control. **B**, Caspase 3/7 activity in control or *ZRSR2* knockout cells after stimulation with LPS or R848 compared with control sgRNA-expressing cells. **C**, Relative growth of control and *ZRSR2* knockout cells, with wild-type *ZRSR2* reexpression or empty vector control, is shown in normal medium (left) or in medium containing LPS (right). **D**, Caspase 3/7 activity in control and *ZRSR2* knockout (KO) cells, with wild-type *ZRSR2* reexpression or empty vector control, is shown after treatment with LPS or TRAIL. In **A** to **D**, $n = 3$ biologically independent replicates, groups compared by *t* test. **E**, Western blot for IRF7, TRAIL, *ZRSR2*, and β -actin in parental, nontargeting control, and *ZRSR2* knockout CAL1 cells, with or without *ZRSR2* reexpression, 24 hours after stimulation with LPS or vehicle. **F**, Western blot for IRF7, *ZRSR2*, and β -actin in wild-type or *ZRSR2* knockout CAL1 cells, BPDCN PDXs of the indicated genotypes, or normal pDCs, with and without LPS (CAL1) or R848 (BPDCN and normal pDCs) treatment. **G**, Model for BPDCN-associated mutations' contribution to disease pathogenesis. Normal pDCs respond to inflammation via TLR signaling to IRF proteins, such as IRF7, which causes production of inflammatory mediators, such as type 1 interferons and TRAIL, and promotion of a feedback loop that leads to activation-induced apoptosis. pDCs with *ZRSR2* mutations and likely also in the presence of other BPDCN-associated alterations are relatively protected from activation-induced apoptosis because they have impaired upregulation of IRF7 and downstream inflammatory mediators.



pDCs, similar to *ZRSR2*-mutant BPDCN cells, harbored signatures of decreased pDC activation and impaired type 1 interferon-dependent signaling. We also detected a higher frequency of missplicing events in the presence of *Zrsr2*, *Tet2*, and *Zrsr2/Tet2* mutation. Similar to what we observed in BPDCN, pDCs harboring these mutations accumulated several types of aberrant splicing (Fig. 7D). Comparison of each group revealed genotype-specific patterns, such as *Zrsr2* mutation associated with a bias toward U12-type IR events, as we observed in human BPDCN cells with *ZRSR2* mutations (Supplementary Fig. S8C). Mutation of *Tet2* alone was associated with splicing abnormalities, including both U2 and U12 IR, and in some genes we observed additivity between *Tet2* and *Zrsr2* mutations to promote increased IR (Fig. 7E). These data are consistent with existing evidence that mutations in *TET2* and other epigenetic modifiers can themselves promote splicing abnormalities and, in concert with splicing factor mutations, produce cooperative effects on splicing and hematopoiesis (33, 45–47). *In vivo*, *Zrsr2/Tet2*-mutant pDCs had impaired activation after systemic exposure to R848 (Fig. 7F). *In vitro* differentiation of dendritic cells from gene-edited multipotent HSPCs yielded *Zrsr2*-, *Tet2*-, or *Zrsr2/Tet2*-mutant pDCs that had hypoactivation and a relative growth advantage, particularly in double-mutant cells after R848 treatment (Fig. 7G). Together, these data support our findings from human cells that *ZRSR2* and *TET2* loss (genes comutated in nearly all *ZRSR2*-mutant BPDCN) promote specific transcriptome changes and provide a clonal advantage to pDCs associated with impaired activation.

DISCUSSION

Our findings contribute to understanding how acquired mutations in hematopoietic cells drive dendritic cell transformation. By sorting tumor cells, we are confident that the somatic mutations detected are not simply passengers of concomitant myeloid malignancies but indeed are present in the BPDCN cells. Furthermore, these data provide evidence that specific mutations, particularly in RNA splicing factors and *TET2*, may have cell type-specific effects on pDCs, impairing their activation and apoptosis in response to TLR stimulation. We propose that innate immune signaling via the TLR–IRF pathway functions as a tumor suppressor in the pDC lineage to prevent malignant transformation. Further work will be required to determine if and how other

mutations in BPDCN affect this pathway and contribute to similar phenotypes.

The high frequency of *ZRSR2* loss-of-function mutations in BPDCN, exclusively in male patients, nominates it as a lineage-specific EXITS gene. By conservative estimation including only unambiguously inactivating alterations, *ZRSR2* mutations are associated with nearly half the male bias of BPDCN. We did not identify *ZRSR2* as an EXITS gene in our prior study (24) because it is most often mutated in BPDCN, MDS, and other myeloid neoplasms such as CMML, cancers that were not included in large-scale sequencing efforts such as The Cancer Genome Atlas. Therefore, this suggests that additional sex-biased cancer genes remain discoverable in understudied diseases. These data also illustrate how identifying functional consequences of a sex-biased mutation may uncover more generalized tumor biology that is relevant even in cases without the specific mutation. For example, sex bias in nonmalignant pDC function has been reported previously, specifically that females have more robust pDC activation and type 1 interferon production than males. This has been attributed to higher female expression of X chromosome (e.g., *TLR7*; ref. 48) or autosomal (e.g., *IRF5*; ref. 49) genes. Our data nominate *ZRSR2* as another candidate gene that, particularly because of its X inactivation escape and higher basal expression in female cells, might render male pDCs less susceptible to activation-induced cell death and could contribute to transformation even in the absence of a mutation.

The effect of *ZRSR2* loss was much more dramatic in TLR-stimulated cells than at baseline. The fact that *IRF7* is regulated by delayed splicing during inflammation (42) again points to the TLR–IRF pathway as a common node that may contribute to BPDCN. We previously found that *IRF7* was among the key pDC genes downregulated in BPDCN using single-cell RNA-seq, suggesting that suppression of this pathway might be a common feature of pDC transformation even in the absence of a splicing factor mutation (14). Distinct acquired alterations in pDCs may converge on TLR signaling to confer a clonal advantage by evasion of activation-induced apoptosis, which could explain why we observed decreased activation after TLR stimulation across BPDCN genotypes. This also suggests that optimal modeling of transformation by BPDCN-associated mutations may need to be performed in the presence of inflammation.

Genetically engineered mouse models that develop spontaneous BPDCN *in vivo* are lacking. Clonal hematopoiesis

Figure 7. BPDCN-associated mutations in hematopoietic progenitors affect dendritic cell differentiation, RNA splicing, and activation signatures *in vivo*. **A**, Schematic of the *in vivo* experiment. sgRNA-transduced Cas9 knock-in bone marrow c-kit⁺ progenitors were injected into lethally irradiated wild-type recipient mice. Each guide was marked with either GFP or tagRFP. The percentage of double-positive cells in recipient bone marrow 8 weeks after transplantation is shown. **B**, Flow cytometry analysis of dendritic progenitor and mature pDCs in sgRNA-positive marrow cells, with groups compared by *t* test. **C**, GSEA of RNA-seq in control (NTG) and *Zrsr2/Tet2*-targeted (DKO) pDCs showing changes in signatures related to DC activation and IFN α receptor-dependent gene expression in the setting of viral infection. Heat map shows expression of the leading-edge genes in GSEA from low (blue) to high (red). MCMV, murine cytomegalovirus. **D**, Missplicing events in *Zrsr2*-, *Tet2*-, and *Zrsr2/Tet2*-targeted (DKO) pDCs. Events in each condition were calculated by pairwise comparisons between control knockout ($n = 3$) and *Zrsr2*-targeted ($n = 2$), *Tet2*-targeted ($n = 3$), and *Zrsr2/Tet2*-targeted (DKO; $n = 3$) biologically independent replicates. The number (and percentage) of events in each condition is shown in a single bar. The colors indicate different event types, intron retention (red), cryptic splice site (green), and exon skip (blue). **E**, Representative RNA-seq reads in *Zrsr2*-, *Tet2*-, and *Zrsr2/Tet2*-targeted (DKO) pDCs visualized on the same scale for *Cecr5* (intron retention associated with *Zrsr2* loss) and *Adam19* (intron retention in *Zrsr2*- and *Tet2*-targeted pDCs with additive retention in *Zrsr2/Tet2*-targeted DKO pDCs). **F**, CD86 upregulation (Δ MFI) *in vivo* after systemic treatment with R848 compared with vehicle in control (NTG) or *Zrsr2/Tet2*-targeted DKO bone marrow pDCs ($n = 3$ independent animals/group, compared by *t* test). **G**, Left two panels, percentage of GFP⁺/tagRFP⁺ cells representing the indicated genotypes from *in vitro* cultures of Cas9 transgenic bone marrow expressing the indicated sgRNAs after vehicle or R848 treatment. Right, CD80 upregulation (Δ MFI) on pDCs of the indicated genotypes from R848 compared with vehicle-treated cultures. $N = 3$ independent cultures per genotype, groups compared by *t* test.

(CH)-type mutations, such as in *TET2* or *ZRSR2*, on their own are unlikely to be sufficient to cause BPDCN. We saw no BPDCN or obvious clonal evolution, albeit in relatively short-term *in vivo* experiments with *Zrsr2* and/or *Tet2* loss. Similarly, no overt myeloid or dendritic leukemia was seen in two other animal models of *Zrsr2* knockout, with or without *Tet2* comutation, that were followed at least 1 year (50, 51). The VAFs of *ZRSR2* and *TET2* from patients harboring both mutations do not clearly indicate the order of acquisition (Supplementary Table S1), but this could be important for disease modeling and warrants additional investigation (52). Generating a BPDCN phenotype in mouse models may require other cooperating mutations, targeting alterations to a specific pDC maturation state or developmental stage, the addition of chronic inflammation, or skin UV light exposure, all of which will be important future experiments to pursue. Another priority is to develop improved methods to propagate and study primary human pDCs *in vitro* and/or to differentiate human pDCs from gene-edited HSPCs or from donor HSPCs that harbor CH mutations. These types of experiments are currently limited by normal pDCs being postmitotic and sensitive to activation-induced cell death caused by lentiviral infection and other transfection methods (53).

TET2, *ASXL1*, and RNA splicing factor mutations are associated with CH and myeloid malignancies, such as MDS and CMML, that can predate BPDCN (54–56). The pathogenesis model proposed here suggests that specific mutations in CH/MDS/CMML contribute to a pDC pool that is poised for transformation. A testable hypothesis for future clinical research is that patients with these precursor conditions who develop BPDCN are enriched for having a history of abnormal inflammation. These findings also suggest that mutations in patients with myeloid malignancies or in individuals with age-related clonal hematopoiesis (or clonal hematopoiesis of indeterminate potential) may affect pDC response to TLR stimulation and thereby contribute to impaired immunity. In support of this hypothesis, *TET2* regulates *Irf7* expression via DNA methylation and is important for pDC type 1 interferon production and survival during viral infection in a mouse model (57). Similarly, defective type 1 interferon production by pDCs is linked to deleterious *IRF7* variants in patients with inferior outcomes during COVID-19/SARS-CoV-2 infection, a subgroup that is also male-biased and older than the general population (58). Our data suggest that age-associated CH mutations, such as in *TET2* or *ZRSR2*, might also contribute to these hypoactive pDC phenotypes.

Finally, there may be therapeutic implications of these data. Splicing modulator drugs are in development, and malignancies with splicing factor mutations are more sensitive to these agents (59). Patients with BPDCN, stratified by the presence of a splicing factor mutation or RNA mis-splicing pattern, could be included in splicing modulator clinical trials. Also, the UV mutational signature enrichment we observed may indicate BPDCN as a candidate for immune checkpoint blockade (ICB). ICB is only modestly active in other myeloid malignancies (60), but the cancers tested (AML, MDS) do not have a UV signature. In contrast, UV signatures predict response to checkpoint blockade in solid tumors, possibly due to qualitative differences in tumor

neoantigens (61). PD-L1 protein is expressed in approximately half of BPDCN (62), which also supports clinical evaluation of ICB via PD-1/PD-L1 in the disease. Last, we previously found that BPDCN is highly dependent on BCL2 and sensitive to the BCL2 inhibitor venetoclax (34). We do not yet know if this is directly related to splicing mutations and impaired activation-induced apoptosis, but the data presented here provide additional rationale for evaluating BCL2 inhibition in BPDCN.

Genes mutated in BPDCN are similar to those in MDS and AML. However, many clinical characteristics of BPDCN and AML are distinct, including epidemiology, clinical presentation, pathology, and response to certain therapies. These data suggest a mechanism by which the consequences of the same gene mutation (the “seed”; e.g., *ZRSR2*) could have lineage-specific effects based on cell context (the dendritic cell “soil”). The TLR-IRF7-type 1 interferon-apoptosis axis that is dysfunctional in BPDCN may not be the target of the same splicing mutations in other, even closely related, malignancies. This highlights the need to study BPDCN and other rare cancers as unique entities and to consider the importance of cellular milieu when evaluating the function of cancer genes.

METHODS

Patient Samples

All studies were approved by local institutional review boards and conformed to guidelines for ethical research conduct in the Declaration of Helsinki, and patients provided written informed consent.

Cell Lines

The 293T packaging cells were obtained from ATCC. CAL1 cells, a male BPDCN cell line that has a *TET2* p.Q481fs* nonsense mutation at 0.97 VAF, were provided by T. Maeda (Nagasaki University). Cell line identity was verified by short tandem repeat profiling in the Dana-Farber Cancer Institute (DFCI) Molecular Diagnostics Core, and cells were verified to be *Mycoplasma*-free by regular testing at least every 6 months. CAL1 cells were cultured in RPMI 1640 supplemented with 10% FBS, penicillin-streptomycin (Gibco, 15140122), and 1% GlutaMAX (Gibco, 35050061). The 293T packaging cells were cultured in DMEM supplemented with 10% FBS and penicillin-streptomycin. Proliferation and apoptosis were measured at the indicated times starting with a concentration of 2×10^5 cells/mL. Proliferation was measured by CellTiter-Glo (Promega, G7572), and caspase activity was measured by Caspase-Glo 3/7 (Promega, G8092).

Primary pDC/BPDCN Cell Isolation and Stimulation

Peripheral blood mononuclear cells were isolated by density gradient centrifugation (Ficoll-Paque PLUS, 17-1440-03; GE Healthcare) from healthy donors. Normal pDCs were enriched using magnetic beads (130-097-415; Miltenyi Biotec) for transcriptomes. CD123⁺BDCA2⁺ cells were sorted for normal pDCs, and CD45^{dim}CD123⁺ cells were sorted for BPDCN PDX tumor cells using a FACSAria (BD Biosciences). For stimulation experiments, pDCs were collected by negative selection using the EasySep Human Plasmacytoid DC Isolation Kit (#17977; StemCell Technologies) to avoid activation by sorting. In all cases, pDCs and BPDCN (from patient and PDX) were >95% pure by flow cytometry. CAL1 cells were seeded at 2×10^5 /mL, and BPDCN tumor cells and normal pDCs were seeded at 1×10^5 /mL. Cells were stimulated with either 1 μ g/mL LPS (L3129; Sigma-Aldrich), 1 μ g/mL R848 (tlrl-r848; Invitrogen), or 1 μ g/mL

TRAIL (#752906, 100 ng/mL; BioLegend) for 24 hours. Supernatants were collected and cytokines were measured by either Bio-Plex Pro (#17AL001M; Bio-Rad) or ProcartaPlex (PPX-24; Thermo Fisher). Cells were stained with 7-AAD, Annexin V, anti-CD80, and anti-DR5 for analysis of viability and activation.

Lentiviral Infections

The 293T cells were transfected with 10.8 μ g psPAX2, 2.4 μ g pVSV-G, and 10.8 μ g of a lentiviral expression vector with Lipofectamine 2000 (11668500; Thermo Fisher). Viral supernatant was harvested 48 and 72 hours after transfection and concentrated by ultracentrifugation at $23,000 \times g$ for 2 hours at 4°C. Then, 2×10^5 cells were infected in the presence of 1.5 mL of viral supernatant and 4 μ g/mL polybrene (SC-134220; Santa Cruz Biotechnology).

Animal Experiments Including Mouse

Bone Marrow-Derived pDCs

All animal experiments were performed with approval from the DFCI Animal Care and Use Committee. C57BL/6J and Rosa-Cas9 knock-in mice [B6J.129(Cg)-Gt (ROSA)26Sor^{tm1.1(CAG-cas9*,-EGFP)/Fzh}/J] were purchased from Jackson Laboratory (026179). Cas9 knock-in mice were sacrificed and bone marrow cells were harvested from legs, iliac bones, and spine for transplantation. CD117/c-kit⁺ cells were sorted by using magnetic beads (#130-094-224; Miltenyi Biotec) after red cell lysis. After culture in StemSpan SFEM with 50 ng/mL SCF (1320-01; Gold Bio Technology) and 50 ng/mL TPO (1320-06; Gold Bio Technology) overnight, CD117/c-kit⁺ cells were infected with virus particles in the presence of 4 μ g/mL polybrene. Transduced cells were injected into the tail vein of lethally irradiated (5.5 Gy \times two split doses) C57BL/6J mice with rescue marrow. The experiment was performed twice with five mice/group with similar results; in the first experiment, donors and recipients were female, and in the second experiment, donors and recipients were male. Animals were sacrificed 8 weeks after the transplantation. Bone marrow and splenocytes were harvested for analysis. For generation of bone marrow-derived pDCs, transduced cells were cultured in RPMI 1640 supplemented with 10% FBS, mouse Flt3-ligand (#250-31L, 100 ng/mL; Peprotech), and 2-mercaptoethanol (M3138, 50 μ mol/L; Sigma-Aldrich) for 7 days. For *in vivo* treatment with TLR ligand, mice were injected with R848 (tlrl-r848, 5 μ g in 200 μ L PBS; Invitrogen) via the tail vein.

Plasmids for cDNA and shRNA Expression and CRISPR/Cas9 Gene Targeting

shRNAs were subcloned into a Tet-on pLKO-puro (#21915; Addgene) via AgeI and EcoRI restriction sites. shRNAs were induced with 1 μ g/mL doxycycline after selecting transduced cells in 1 μ g/mL puromycin. sgRNAs were subcloned into a lentiviral expression vector that coexpresses GFP (pLKO5.sgRNA.EFS.GFP; #57822; Addgene) or tagRFP (pLKO5.sgRNA.EFS.tagRFP; #57823; Addgene) via the BsmBI restriction site. Cell lines stably expressing the Cas9 nuclease were generated by infection with the empty lentiCRISPRv2 lentivirus (#52961, not containing an sgRNA guide; Addgene) using standard methods (<https://www.addgene.org/viral-vectors/lentivirus/lenti-guide/>). Cells were selected in puromycin, and FLAG-Cas9 expression was confirmed by Western blot. Cas9-expressing cell lines were infected at a density of 2×10^5 cells in 1.5 mL media in the presence of 4 μ g/mL polybrene (SC-134220; Santa Cruz Biotechnology). sgRNA-resistant human ZRSR2 DNA fragment was synthesized by Twist Bioscience and cloned into pRRLidTomato. sgRNA, shRNA, and sgRNA-resistant ZRSR2 cDNA sequences are in the Supplementary Methods.

Primary pDC and Cell Line siRNA Transfection

siZRSR2 (L-006596-02; Dharmacon), siUPFI (L-011763-00; Dharmacon), Non-targeting Control Pool siRNA (D-001810-10; Dhar-

macon), and siGLO Cyclophilin B control siRNA (D-001610-01; Dharmacon) were transfected using N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate (DOTAP; #11202375001; Roche Diagnostics) as in Smith and colleagues (53). Equal volumes of siRNA (final concentration 160 nmol/L) and DOTAP were mixed and incubated for 15 minutes at room temperature. The mixture was added on top of cells. pDCs were seeded at 1×10^5 cells/100 μ L in 96-well plates, and CAL1 cells were seeded 2×10^5 cells/mL in 6-well plates. Cells were incubated at 37°C for 24 hours and then washed before performing experiments.

Flow Cytometry

Cells were washed with PBS containing 2% FBS before staining and then incubated with the indicated antibodies for 30 minutes in the dark at 4°C, followed by a final wash in PBS containing 2% FBS and analyzed. In the case of murine samples, we lysed red blood cells prior to staining. Flow cytometry was performed using a BD LSR Fortessa X-20 and analyzed using FlowJo software, version 10. Antibodies for flow cytometry are in Supplementary Table S5. Cell surface markers for HSPC populations are in Supplementary Table S6.

Western Blotting

Samples were prepared by lysing in RIPA buffer (BP-115; Boston BioProducts) with protease inhibitor cocktail (862209; Thermo Fisher Scientific) and sonicated before quantification by BCA assay (23225; Thermo Fisher Scientific). Samples were prepared with SDS sample buffer (BP-110R; Boston BioProducts), boiled for 10 minutes at 98°C, and recovered by spinning at $12,000 \times g$ for 5 minutes at 4°C before loading onto the gel. The gel was run for 80 minutes at 120 V in SDS running buffer (BP-177; Boston BioProducts) before being transferred to a polyvinylidene difluoride membrane (7462; Thermo Fisher Scientific) for 7 minutes at 20 V using iBlot 2 (Thermo Fisher Scientific). Blots were blocked in 5% dried milk (A0830; AppliChem) in Tris-buffered saline (TBS) with 0.1% Tween-20 for 1 hour before being incubated overnight in antibodies recognizing ZRSR2 (kindly provided by Dr. Michael Green, University of Massachusetts Medical School, 1:2,000), IRF7 (#4920, 1:1,000; Cell Signaling Technology), TRAIL (#3219, 1:1,000; Cell Signaling Technology), UPFI (#ab109363, 1:10,000; Abcam), or β -actin (A5441, 1:10,000; Sigma-Aldrich). The blots were washed three times in TBS with 0.1% Tween-20 before being incubated with either rabbit (SC-2004; Santa Cruz Biotechnology) or mouse (SC-2005; Santa Cruz Biotechnology) secondary horseradish peroxidase-conjugated antibodies before being imaged using ECL substrate (170-5061; Bio-Rad) on an ImageQuant LAS-4000 (28-9607-59AB; GE Healthcare).

T7 Endonuclease (T7E1) Assay

Genomic DNA from mouse bone marrow cells was extracted by the DNeasy Blood and Tissue Kit (#69504; Qiagen). The DNA region containing sgRNA target sites was amplified by PCR using specific primers (Zrsr2 Forward, CCCATGGCATCTTTGTCTATAATCT; Zrsr2 Reverse, GCTCAGCTAAGCACTTACTCAATG; Tet2_Foreward, ACATACTCCTCAGACGAGG; Tet2_Reverse, CTGGCATGTACCTG GATTGC). PCR products were purified with NucleoSpin Gel and PCR Clean-Up (#740609; Takara Bio). Then, 400 ng of PCR products mixed with NEB buffer 2 was denatured at 95°C for 5 minutes and ramped down to 25°C. T7 Endonuclease 1 (M0302; NEB) was added to the mixture and incubated at 37°C for 15 minutes. Next, 0.25 mol/L EDTA was added to stop the reaction, and samples were analyzed on 2% agarose gel.

CRISPR/Cas9 Editing Site Sequencing

Genomic DNA was extracted from GFP⁺/tagRFP⁺ mouse Lineage-c-kit⁺ bone marrow cells using TRIzol (15596018; Life Technologies). PCR was performed spanning the predicted Cas9 cut sites, using

the primers as below. Illumina-compatible adapters with unique barcodes were ligated onto each sample during library construction. Libraries were pooled in equimolar concentrations for multiplexed sequencing on the Illumina MiSeq platform with 2×150 run parameters. Upon completion of the sequencing run, data were demultiplexed and subsequently entered into an automated *de novo* assembly pipeline. Sequencing and analysis were performed by the CCIB DNA Core Facility at Massachusetts General Hospital (*Tet2* For, GGGGGTTGGAGCAAGTACAAA; *Tet2* Rev, GCCCTGTAGACACGAAGC; *Zrsr2* For, CACACTCCCATCTTCACTGCT; *Zrsr2* Rev, CAGCTAAGCACTTACTCAATGAAGT).

RT-PCR

RNA was extracted from cell lines using TRIzol (15596018; Life Technologies) and quantified via NanoDrop. The High-Capacity cDNA Reverse Transcriptase Kit (4368814; Thermo Fisher Scientific) was used to generate cDNA. qRT-PCR was performed for human *IRF7*, using *GAPDH* as the internal control, using the primers as below, and SYBR Green PCR master mix per the manufacturer's instructions (Thermo Fisher Scientific, 4367659). Relative quantification was calculated using the $\Delta\Delta C_t$ method. *IRF7* For, TACCATCTACCTGGGCTTCG; *IRF7* Rev, GAAGA-CACACCCTCA CGCTG; *IRF7* intron4 For, TGCACCTGGACGGACACTTTAG; *IRF7* intron4 Rev, CCTCCTAATTCTCCAGCTCC; *GAPDH* For, GCACCGT CAAGGCTGAGAAC; *GAPDH* Rev, TGGTGA-AGACGCCAGTGG. For RT-PCR, the following primers were used: *DERL3* For, GGC CGACTTCGCTTTCATGTTTC; *DERL3* Rev, CAGGTCCACGAGG ATGGAGT.

IRF7 Knock-In Cell Line Generation

The FLAG tag of pFETCh_Donor (#63934; Addgene) was replaced with a V5 tag via the *KasI* and the *BsrGI* restriction sites. Homology arm 1 and homology arm 2 were designed for intronless wild-type *IRF7* and inactive form *IRF7* (9A) with Gibson Assembly tails and synthesized by Twist Bioscience. Homology arms were subcloned into pFETCh_Donor with Gibson Assembly (#E2611; New England Biolabs). sgRNAs were subcloned into pXPR_BRD202 via the *BsmBI* restriction site. Then, 12 μg pFETCh, 6 μg of each sgRNA, 60 μL Lipofectamine, and 3 mL Opti-MEM (#11058021; Life Technologies) were mixed and incubated for 20 minutes at room temperature, then added to 1 million Cas9-expressing CAL1 cells in 10 mL media. Cells were selected in G418 (#MT61234RG; Fisher Scientific) and V5 tag expression was confirmed by Western blot. *IRF7* sgRNA and homology arm sequences are in the Supplementary Methods.

Whole-Exome Sequencing and Analysis

Tumor and paired germline DNA samples were collected and prepared for WES using the Agilent SureSelect Human All Exon V5 (50 mol/L) capture. Sequencing was performed on the HiSeq4000 platform with a 150 base pair paired-end protocol targeted to 100 \times mean coverage. The sequences were generated as 90 of 100 base paired-end reads using Illumina base calling software (version 1.7). The adapter sequences and low-quality reads were filtered from the raw sequencing data, and the "clean data" were aligned by a Burrows-Wheeler Aligner (63) with the reference of human genome build37 (hg19). The BAM files were validated by steps of fixing mate information of the alignment, adding read group information, and removing duplicate reads and then applied to variant calling analysis using the GATK toolkit (<https://gatk.broadinstitute.org/hc/en-us>). The reference (hg19) and germline variant sites were used to detect somatic or tumor-specific mutations and copy number alterations. The details of the methods in the GATK toolkit are described elsewhere (64, 65). The identified BPDCN somatic mutations were analyzed with those reported for AML and skin melanoma (66) for the presence of previously defined global DNA

mutational signatures in the COSMIC database (20) using the R package, "MutationalPatterns" (67).

RNA Sequencing and Analysis

Samples from pDCs, patients with BPDCN, PDXs, CAL1, and mouse models were collected for total RNA sequencing using the Arc-turus PicoPure RNA Isolation Kit (Life Technologies). Libraries were prepared using the Ovation kit (#0340; Nugen) using 50 ng input total RNA and 20 cycles of amplification. The Illumina Hi-Seq platform was used to generate single or paired-end sequencing results. The raw FASTQ data were analyzed by the VIPER pipeline (68), which combines STAR (69) alignment (mapped to hg19 or mm10) and gene expression analysis such as unsupervised clustering, principal component analysis based on Cufflinks (70), and differential expression with DESeq2 (71). The expression data were used for pathway enrichment analysis with GSEA and gene set variation analysis (72, 73).

Differential Splicing Analysis

Splicing events were identified as described in Madan and colleagues (27). The method calculates a missplicing index (MSI) for each splicing event in comparison to the reference genome (human hg19 or mouse mm10) and classifies them as IR, exon skip, and incorrect splice site usage. The difference in MSI between two samples was used for direct comparisons by defining the delta MSI (ΔMSI) as the difference in MSI at a given site between two samples. The statistical significance of differences in splicing events was evaluated by Fisher exact test with adjusted *P* value for multiple hypothesis testing. Differences with $\Delta\text{MSI} > 0.2$ and $P \leq 0.05$ were considered significant.

Data Visualization and Availability

Analysis results were visualized using R 3.5.2 (R Foundation for Statistical Computing; ref. 74) and Python. A computation plot was created using the "GenVisR" package in R (75). RNA-seq data are deposited in the Gene Expression Omnibus, accession number GSE184656.

Authors' Disclosures

K. Togami reports grants from the Sumitomo Life Welfare and Culture Foundation during the conduct of the study. M. Ghandi reports being a current Monte Rosa Therapeutics employee and stockholder and a founding member of Cambridge Data Science LLC. M. Seiler reports other support from H3 Biomedicine outside the submitted work. M. Konopleva reports other support from AbbVie, other support from Genentech, other support from F. Hoffman-La Roche, other support from Stemline Therapeutics, other support from Eli Lilly, other support from Calithera, other support from Aplynx, other support from Agios, other support from Ascentage, other support from AstraZeneca, other support from Rafael Pharmaceutical, other support from Sanofi, other support from Forty Seven, other support from Reata, other support from Janssen, other support from Novartis, other support from Eli Lilly, and other support from Reata outside the submitted work. N. Pemmaraju reports personal fees from Pacylex Pharmaceuticals, personal fees from ImmunoGen, personal fees from Bristol Myers Squibb, personal fees from Clearview Healthcare Partners, personal fees from Astellas Pharma US, Inc., personal fees from Protagonist Therapeutics, Inc., personal fees from Triptych Health Partners, personal fees from CIT Biopharma, grants and nonfinancial support from Affymetrix, grants from SagerStrong Foundation, grants from US Department of Defense, personal fees from Incyte, personal fees and nonfinancial support from Novartis, personal fees from LFB Biotechnologies, personal fees, nonfinancial support, and other support from Stemline Therapeutics, personal fees and other support from Celgene, personal fees, nonfinancial support, and other support from AbbVie, personal fees, nonfinancial support, and other support from MustangBio, personal

fees from Roche Diagnostics, personal fees and other support from DAVA Oncology, personal fees from Springer Science + Business Media LLC, personal fees from Aptitude Health, personal fees from NeoPharm Israel, personal fees from CareDx, Inc., nonfinancial support from Samus Therapeutics, nonfinancial support from Cellectis, nonfinancial support from Daiichi Sankyo, and nonfinancial support from Plexxikon outside the submitted work. O. Abdel-Wahab reports having served as a consultant for H3B Biomedicine, Foundation Medicine Inc., Merck, Prelude Therapeutics, and Janssen, and is on the Scientific Advisory Board of Envisagenics Inc., AlChem, and Pfizer Boulder; and has received prior research funding from H3B Biomedicine and LOXO Oncology unrelated to the current manuscript. A.A. Lane reports grants from National Cancer Institute, grants from Department of Defense, grants from Mark Foundation for Cancer Research, grants from Doris Duke Charitable Foundation, grants from Bertarelli Rare Cancers Fund, grants from Ludwig Center at Harvard, and grants from American Society of Hematology during the conduct of the study; grants from Stemline Therapeutics, grants from AbbVie, personal fees from Qiagen, and personal fees from N-of-One outside the submitted work. No disclosures were reported by the other authors.

Authors' Contributions

K. Togami: Conceptualization, investigation, writing—original draft. **S. Chung:** Investigation, writing—review and editing. **V. Madan:** Investigation, writing—review and editing. **C.A.G. Booth:** Investigation, writing—review and editing. **C.M. Kenyon:** Investigation, writing—review and editing. **L. Cabal-Hierro:** Investigation. **J. Taylor:** Investigation, writing—review and editing. **S.S. Kim:** Investigation. **G.K. Griffin:** Investigation, writing—review and editing. **M. Ghandi:** Investigation. **J. Li:** Investigation. **Y.Y. Li:** Investigation. **F. Angelot-Delettre:** Resources, investigation. **S. Biichle:** Resources, investigation. **M. Seiler:** Resources, investigation. **S. Buonamici:** Resources, investigation. **S.B. Lovitch:** Investigation. **A. Louissaint:** Investigation. **E.A. Morgan:** Investigation. **F. Jardin:** Resources, investigation. **P.P. Piccaluga:** Resources, investigation. **D.M. Weinstock:** Resources, writing—review and editing. **P.S. Hammerman:** Investigation. **H. Yang:** Investigation, methodology. **M. Konopleva:** Resources. **N. Pemmaraju:** Resources, writing—review and editing. **F. Garnache-Ottou:** Resources, investigation. **O. Abdel-Wahab:** Resources, investigation. **H. Koeffler:** Resources, investigation. **A.A. Lane:** Conceptualization, resources, supervision, funding acquisition, investigation, writing—original draft, writing—review and editing.

Acknowledgments

This work was supported by the Sumitomo Life Welfare and Culture Foundation (to K. Togami), the NCI R37 CA225191 (to A.A. Lane) and R35 CA231958 (to D.M. Weinstock), the Department of Defense W81XWH-20-1-0683 (to M. Konopleva, N. Pemmaraju, O. Abdel-Wahab, and A.A. Lane), the Damon Runyon Cancer Research Foundation (to G.K. Griffin), Mark Foundation for Cancer Research (to A.A. Lane), Doris Duke Charitable Foundation (to A.A. Lane), Bertarelli Rare Cancers Fund (to A.A. Lane), Ludwig Center at Harvard (to A.A. Lane), and the American Society of Hematology (to A.A. Lane).

The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

Note

Supplementary data for this article are available at Cancer Discovery Online (<http://cancerdiscovery.aacrjournals.org/>).

Received October 16, 2020; revised August 17, 2021; accepted October 1, 2021; published first October 6, 2021.

REFERENCES

- Deconinck E, Petrella T, Garnache Ottou F. Blastic plasmacytoid dendritic cell neoplasm: clinical presentation and diagnosis. *Hematol Oncol Clin North Am* 2020;34:491–500.
- Garnache-Ottou F, Vidal C, Biichle S, Renosi F, Poret E, Pagadoy M, et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients? *Blood Adv* 2019;3:4238–51.
- Taylor J, Haddadin M, Upadhyay VA, Grussie E, Mehta-Shah N, Brunner AM, et al. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. *Blood* 2019;134:678–87.
- Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. *Haematologica* 2013;98:239–46.
- Bastidas Torres AN, Cats D, Mei H, Fanoni D, Gliozzo J, Corti L, et al. Whole-genome analysis uncovers recurrent IKZF1 inactivation and aberrant cell adhesion in blastic plasmacytoid dendritic cell neoplasm. *Genes Chromosomes Cancer* 2020;59:295–308.
- Jardin F, Ruminy P, Parmentier F, Troussard X, Vaida I, Stamatoullas A, et al. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm. *Br J Haematol* 2011;153:413–6.
- Lucioni M, Novara F, Fiandrino G, Riboni R, Fanoni D, Arra M, et al. Twenty-one cases of blastic plasmacytoid dendritic cell neoplasm: focus on biallelic locus 9p21.3 deletion. *Blood* 2011;118:4591–4.
- Menezes J, Acquadro F, Wiseman M, Gomez-Lopez G, Salgado RN, Talavera-Casanas JG, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm. *Leukemia* 2014;28:823–9.
- Sapienza MR, Abate F, Melle F, Orecchioni S, Fuligni F, Etebari M, et al. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. *Haematologica* 2019;104:729–37.
- Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. *Am J Hematol* 2013;88:1055–61.
- Brunetti L, Di Battista V, Venanzi A, Schiavoni G, Martelli MP, Ascani S, et al. Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. *Leukemia* 2017;31:1238–40.
- Luskin MR, Kim AS, Patel SS, Wright K, LeBoeuf NR, Lane AA. Evidence for separate transformation to acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm from a shared ancestral hematopoietic clone. *Leuk Lymphoma* 2020;61:2258–61.
- Chaperot L, Bendriss N, Manches O, Gressin R, Maynadie M, Trimoreau F, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. *Blood* 2001;97:3210–7.
- Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. *Science* 2017;356:eaah4573.
- Sapienza MR, Fuligni F, Agostinelli C, Tripodo C, Righi S, Laginestra MA, et al. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF- κ B pathway inhibition. *Leukemia* 2014;28:1606–16.
- Kluk MJ, Lindsley RC, Aster JC, Lindeman NI, Szeto D, Hall D, et al. Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies. *J Mol Diagn* 2016;18:507–15.
- Figuroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell* 2010;18:553–67.

18. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. *N Engl J Med* 2011;365:127–38.
19. Sichien D, Scott CL, Martens L, Vanderkerken M, Van Gassen S, Plantinga M, et al. IRF8 transcription factor controls survival and function of terminally differentiated conventional and plasmacytoid dendritic cells, respectively. *Immunity* 2016;45:626–40.
20. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. *Nature* 2013;500:415–21.
21. Jardin F, Callanan M, Penther D, Ruminy P, Troussard X, Kerckaert JP, et al. Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease. *Leukemia* 2009;23:698–707.
22. Yoshida K, Sanada M, Shiraiishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. *Nature* 2011;478:64–9.
23. Tukiainen T, Villani AC, Yen A, Rivas MA, Marshall JL, Satija R, et al. Landscape of X chromosome inactivation across human tissues. *Nature* 2017;550:244–8.
24. Dunford A, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, et al. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. *Nat Genet* 2017;49:10–6.
25. Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. *Cell Rep* 2018;23:282–96.
26. Liu Z, Yoshimi A, Wang J, Cho H, Chun-Wei Lee S, Ki M, et al. Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization. *Cancer Discov* 2020;10:806–21.
27. Madan V, Kanojia D, Li J, Okamoto R, Sato-Otsubo A, Kohlmann A, et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. *Nat Commun* 2015;6:6042.
28. Wong JJ, Ritchie W, Ebner OA, Selbach M, Wong JW, Huang Y, et al. Orchestrated intron retention regulates normal granulocyte differentiation. *Cell* 2013;154:583–95.
29. Shen H, Zheng X, Luecke S, Green MR. The U2AF35-related protein Urp contacts the 3' splice site to promote U12-type intron splicing and the second step of U2-type intron splicing. *Genes Dev* 2010;24:2389–94.
30. Turunen JJ, Niemela EH, Verma B, Frilander MJ. The significant other: splicing by the minor spliceosome. *Wiley Interdiscip Rev RNA* 2013;4:61–76.
31. Madan V, Li J, Zhou S, Teoh WW, Han L, Meggendorfer M, et al. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes. *Am J Hematol* 2020;95:133–43.
32. Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC, Ramakrishnan A, et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. *Cancer Cell* 2015;27:617–30.
33. Obeng EA, Chappell RJ, Seiler M, Chen MC, Campagna DR, Schmidt PJ, et al. Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation. *Cancer Cell* 2016;30:404–17.
34. Montero J, Stephansky J, Cai T, Griffin GK, Cabal-Hierro L, Togami K, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. *Cancer Discov* 2017;7:156–64.
35. Beird HC, Khan M, Wang F, Alfayez M, Cai T, Zhao L, et al. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN). *Blood Cancer J* 2019;9:99.
36. Swiecki M, Wang Y, Vermi W, Gilfillan S, Schreiber RD, Colonna M. Type I interferon negatively controls plasmacytoid dendritic cell numbers in vivo. *J Exp Med* 2011;208:2367–74.
37. Blum A, Chaperot L, Molens JP, Foissaud V, Plantaz D, Plumas J. Mechanisms of TRAIL-induced apoptosis in leukemic plasmacytoid dendritic cells. *Exp Hematol* 2006;34:1655–62.
38. Chaperot L, Blum A, Manches O, Lui G, Angel J, Molens JP, et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. *J Immunol* 2006;176:248–55.
39. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. *Nature* 2005;434:772–7.
40. Romieu-Mourez R, Solis M, Nardin A, Goubau D, Baron-Bodo V, Lin R, et al. Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages. *Cancer Res* 2006;66:10576–85.
41. Frankiw L, Majumdar D, Burns C, Vlach L, Moradian A, Sweredoski MJ, et al. BUD13 promotes a type I interferon response by countering intron retention in Irf7. *Mol Cell* 2019;73:803–14.
42. Majumdar DS, Frankiw L, Burns CH, Garcia-Flores Y, Baltimore D. Programmed delayed splicing: a mechanism for timed inflammatory gene expression. *bioRxiv* 2018.
43. Patel AA, McCarthy M, Steitz JA. The splicing of U12-type introns can be a rate-limiting step in gene expression. *EMBO J* 2002;21:3804–15.
44. Andrienas KK, Ramlall V, Kurland J, Leung B, Harbaugh AG, Siggers T. DNA-binding landscape of IRF3, IRF5 and IRF7 dimers: implications for dimer-specific gene regulation. *Nucleic Acids Res* 2018;46:2509–20.
45. Marina RJ, Sturgill D, Bailly MA, Thenoz M, Varma G, Prigge MF, et al. TET-catalyzed oxidation of intragenic 5-methylcytosine regulates CTCF-dependent alternative splicing. *EMBO J* 2016;35:335–55.
46. Martinez-Valiente C, Garcia-Ruiz C, Roson B, Liquori A, Gonzalez-Romero E, Fernandez-Gonzalez R, et al. Aberrant alternative splicing in U2af1/Tet2 double mutant mice contributes to major hematological phenotypes. *Int J Mol Sci* 2021;22:6963.
47. Yoshimi A, Lin KT, Wiseman DH, Rahman MA, Pastore A, Wang B, et al. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis. *Nature* 2019;574:273–7.
48. Webb K, Peckham H, Radziszewska A, Menon M, Oliveri P, Simpson F, et al. Sex and pubertal differences in the type I interferon pathway associate with both X chromosome number and serum sex hormone concentration. *Front Immunol* 2018;9:3167.
49. Griesbeck M, Ziegler S, Laffont S, Smith N, Chauveau L, Tomezsko P, et al. Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN- α production in women. *J Immunol* 2015;195:5327–36.
50. Madan V, Cao Z, Teoh WW, Dakle P, Han L, Shyamsunder P, et al. ZRSR1 cooperates with ZRSR2 in regulating splicing of U12-type introns in murine hematopoietic cells. *Haematologica* 2021 Mar 11 [Epub ahead of print].
51. Inoue D, Polaski JT, Taylor J, Castel P, Chen S, Kobayashi S, et al. Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition. *Nat Genet* 2021;53:707–18.
52. Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of mutation order on myeloproliferative neoplasms. *N Engl J Med* 2015;372:601–12.
53. Smith N, Vidalain PO, Nisole S, Herbeval JP. An efficient method for gene silencing in human primary plasmacytoid dendritic cells: silencing of the TLR7/IRF-7 pathway as a proof of concept. *Sci Rep* 2016;6:29891.
54. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med* 2014;371:2488–98.
55. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. *Leukemia* 2014;28:241–7.
56. Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, et al. Age-related mutations and chronic myelomonocytic leukemia. *Leukemia* 2016;30:906–13.
57. Ma S, Wan X, Deng Z, Shi L, Hao C, Zhou Z, et al. Epigenetic regulator CXXC5 recruits DNA demethylase Tet2 to regulate TLR7/9-elicited IFN response in pDCs. *J Exp Med* 2017;214:1471–91.
58. Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science* 2020;370:eabd4570.
59. Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. *Nat Med* 2016;22:672–8.

60. Bewersdorf JP, Stahl M, Zeidan AM. Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. *Expert Rev Anticancer Ther* 2019;19:393–404.
61. Pham TV, Boichard A, Goodman A, Riviere P, Yeerna H, Tamayo P, et al. Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. *Mol Oncol* 2020;14:1680–94.
62. Aung PP, Sukswai N, Nejati R, Loghavi S, Chen W, Torres-Cabala CA, et al. PD1/PD-L1 expression in blastic plasmacytoid dendritic cell neoplasm. *Cancers* 2019;11:695.
63. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* 2009;25:1754–60.
64. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. *Nature* 2011;470:214–20.
65. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and analysis of multiple myeloma. *Nature* 2011;471:467–72.
66. Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. *Nature* 2020;578:94–101.
67. Blokzijl F, Janssen R, van Boxtel R, Cuppen E. MutationalPatterns: comprehensive genome-wide analysis of mutational processes. *Genome Med* 2018;10:33.
68. Cornwell M, Vangala M, Taing L, Herbert Z, Koster J, Li B, et al. VIPER: visualization pipeline for RNA-seq, a snakemake workflow for efficient and complete RNA-seq analysis. *BMC Bioinformatics* 2018;19:135.
69. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* 2013;29:15–21.
70. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, et al. Transcript assembly and quantification by RNA-seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat Biotechnol* 2010;28:511–5.
71. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.
72. Hanzelmann S, Castelo R, Guinney J. GSEA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinformatics* 2013;14:7.
73. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;102:15545–50.
74. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2018.
75. Skidmore ZL, Wagner AH, Lesurf R, Campbell KM, Kunisaki J, Griffith OL, et al. GenVisR: genomic visualizations in R. *Bioinformatics* 2016;32:3012–4.